These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 24651624)

  • 1. Use of strontium ranelate and risk of acute coronary syndrome: cohort study.
    Svanström H; Pasternak B; Hviid A
    Ann Rheum Dis; 2014 Jun; 73(6):1037-43. PubMed ID: 24651624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osteoporosis drugs in real-world clinical practice: an analysis of persistence.
    Iolascon G; Gimigliano F; Orlando V; Capaldo A; Di Somma C; Menditto E
    Aging Clin Exp Res; 2013 Oct; 25 Suppl 1():S137-41. PubMed ID: 24046038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
    Iwamoto J; Takeda T; Sato Y
    Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of strontium ranelate versus risedronate in the treatment of postmenopausal osteoporotic women aged over 75 years.
    Hiligsmann M; Bruyère O; Reginster JY
    Bone; 2010 Feb; 46(2):440-6. PubMed ID: 19716940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gastrointestinal tolerability and patterns of switching in patients treated for primary osteoporosis: the Swedish Adherence Register Analysis (SARA).
    Landfeldt E; Lang A; Robbins S; Ström O
    Calcif Tissue Int; 2011 Sep; 89(3):234-45. PubMed ID: 21695544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hip fractures in users of first- vs. second-generation bisphosphonates.
    Mamdani M; Kopp A; Hawker G
    Osteoporos Int; 2007 Dec; 18(12):1595-600. PubMed ID: 17767369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ischaemic cardiac events and use of strontium ranelate in postmenopausal osteoporosis: a nested case-control study in the CPRD.
    Cooper C; Fox KM; Borer JS
    Osteoporos Int; 2014 Feb; 25(2):737-45. PubMed ID: 24322476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of pharmacological agents in managing osteoporosis in the old old: review of the evidence.
    Inderjeeth CA; Foo AC; Lai MM; Glendenning P
    Bone; 2009 May; 44(5):744-51. PubMed ID: 19130909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nationwide registry-based analysis of cardiovascular risk factors and adverse outcomes in patients treated with strontium ranelate.
    Abrahamsen B; Grove EL; Vestergaard P
    Osteoporos Int; 2014 Feb; 25(2):757-62. PubMed ID: 24322475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. One and two-year persistence with different anti-osteoporosis medications: a retrospective cohort study.
    Reyes C; Tebe C; Martinez-Laguna D; Ali MS; Soria-Castro A; Carbonell C; Prieto-Alhambra D
    Osteoporos Int; 2017 Oct; 28(10):2997-3004. PubMed ID: 28714038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Osteoporosis: non-hormonal treatment.
    Rizzoli R
    Climacteric; 2007 Oct; 10 Suppl 2():74-8. PubMed ID: 17882678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost effectiveness of denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the US.
    Parthan A; Kruse M; Yurgin N; Huang J; Viswanathan HN; Taylor D
    Appl Health Econ Health Policy; 2013 Oct; 11(5):485-97. PubMed ID: 23868102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Osteoporosis and venous thromboembolism: a retrospective cohort study in the UK General Practice Research Database.
    Breart G; Cooper C; Meyer O; Speirs C; Deltour N; Reginster JY
    Osteoporos Int; 2010 Jul; 21(7):1181-7. PubMed ID: 19806285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis.
    Bilezikian JP
    Am J Med; 2009 Feb; 122(2 Suppl):S14-21. PubMed ID: 19187808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of strontium ranelate on markers of cardiovascular risk in postmenopausal osteoporotic women.
    Atteritano M; Catalano A; Santoro D; Lasco A; Benvenga S
    Endocrine; 2016 Jul; 53(1):305-12. PubMed ID: 26304851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in urinary NTX levels in patients with primary osteoporosis undergoing long-term bisphosphonate treatment.
    Iba K; Takada J; Hatakeyama N; Ozasa Y; Wada T; Yamashita T
    J Orthop Sci; 2008 Sep; 13(5):438-41. PubMed ID: 18843458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RisedronatE and ALendronate Intervention over Three Years (REALITY): minimal differences in fracture risk reduction.
    Curtis JR; Westfall AO; Cheng H; Saag KG; Delzell E
    Osteoporos Int; 2009 Jun; 20(6):973-8. PubMed ID: 18946630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response to oral bisphosphonates in subgroups of younger and older postmenopausal women.
    Stovall DW; Beard MK; Barbier S; Chen E; Rosenberg E; de Papp AE
    J Womens Health (Larchmt); 2010 Mar; 19(3):491-7. PubMed ID: 20141367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
    Brecht JG; Kruse HP; Möhrke W; Oestreich A; Huppertz E
    Int J Clin Pharmacol Res; 2004; 24(1):1-10. PubMed ID: 15575171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strontium ranelate treatment in a postmenopausal woman with osteonecrosis of the jaw after long-term oral bisphosphonate administration: a case report.
    Pan WL; Chen PL; Lin CY; Pan YC; Ju YR; Chan CP; Hsu RW
    Clin Interv Aging; 2017; 12():1089-1093. PubMed ID: 28744112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.